JP2015501791A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015501791A5 JP2015501791A5 JP2014540950A JP2014540950A JP2015501791A5 JP 2015501791 A5 JP2015501791 A5 JP 2015501791A5 JP 2014540950 A JP2014540950 A JP 2014540950A JP 2014540950 A JP2014540950 A JP 2014540950A JP 2015501791 A5 JP2015501791 A5 JP 2015501791A5
- Authority
- JP
- Japan
- Prior art keywords
- methoxyethyl
- gataparsen
- m5ru
- manufactured
- thoxyethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 6
- BZRZNGDLBBZGMQ-UHFFFAOYSA-N gataparsen Chemical compound O1C(N2C(NC(=O)C(C)=C2)=O)C(OCCOC)C(O)C1COP(O)(=S)OC(C(C(O1)N2C(NC(=O)C(C)=C2)=O)OCCOC)C1COP(O)(=S)OC(C(C(O1)N2C3=NC=NC(N)=C3N=C2)OCCOC)C1COP(O)(=S)OC(C(C(O1)N2C3=NC=NC(N)=C3N=C2)OCCOC)C1COP(S)(=O)OC1CC(N2C3=C(C(NC(N)=N3)=O)N=C2)OC1COP(O)(=S)OC(C(O1)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(C(OC2COP(O)(=S)OC2C(C(OC2COP(O)(=S)OC2C(C(OC2COP(O)(=S)OC2C(C(OC2CO)N2C(NC(=O)C(C)=C2)=O)OCCOC)N2C3=C(C(NC(N)=N3)=O)N=C2)OCCOC)N2C(NC(=O)C(C)=C2)=O)OCCOC)N2C3=C(C(NC(N)=N3)=O)N=C2)OCCOC)CC1N1C=C(C)C(=O)NC1=O BZRZNGDLBBZGMQ-UHFFFAOYSA-N 0.000 description 4
- 229950006421 gataparsen Drugs 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000007327 Protamines Human genes 0.000 description 2
- 108010007568 Protamines Proteins 0.000 description 2
- 108010002687 Survivin Proteins 0.000 description 2
- 102000000763 Survivin Human genes 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- SRLOHQKOADWDBV-NRONOFSHSA-M sodium;[(2r)-2,3-di(octadecanoyloxy)propyl] 2-(2-methoxyethoxycarbonylamino)ethyl phosphate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCCNC(=O)OCCOC)OC(=O)CCCCCCCCCCCCCCCCC SRLOHQKOADWDBV-NRONOFSHSA-M 0.000 description 1
- 229960002363 thiamine pyrophosphate Drugs 0.000 description 1
- 235000008170 thiamine pyrophosphate Nutrition 0.000 description 1
- 239000011678 thiamine pyrophosphate Substances 0.000 description 1
- YXVCLPJQTZXJLH-UHFFFAOYSA-N thiamine(1+) diphosphate chloride Chemical compound [Cl-].CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N YXVCLPJQTZXJLH-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2011-0117082 | 2011-11-10 | ||
| KR1020110117082A KR101383324B1 (ko) | 2011-11-10 | 2011-11-10 | 신규한 유전자 전달용 조성물 |
| PCT/KR2012/009443 WO2013070010A1 (en) | 2011-11-10 | 2012-11-09 | Novel composition for gene delivery |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015501791A JP2015501791A (ja) | 2015-01-19 |
| JP2015501791A5 true JP2015501791A5 (enExample) | 2015-05-21 |
| JP5923177B2 JP5923177B2 (ja) | 2016-05-24 |
Family
ID=48290305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014540950A Active JP5923177B2 (ja) | 2011-11-10 | 2012-11-09 | 新規な遺伝子伝達用組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9173853B2 (enExample) |
| EP (1) | EP2776056B1 (enExample) |
| JP (1) | JP5923177B2 (enExample) |
| KR (1) | KR101383324B1 (enExample) |
| ES (1) | ES2621403T3 (enExample) |
| WO (1) | WO2013070010A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101494594B1 (ko) | 2011-08-30 | 2015-02-23 | 주식회사 종근당 | 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물 |
| KR101586791B1 (ko) | 2012-12-28 | 2016-01-19 | 주식회사 종근당 | GnRH 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물 |
| US9493430B2 (en) | 2013-01-31 | 2016-11-15 | Chong Kun Dang Pharmaceutical Corp. | Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as CETP inhibitors |
| KR101601035B1 (ko) | 2013-02-28 | 2016-03-08 | 주식회사 종근당 | 키토산 및 액상결정 형성 물질을 포함하는 유전자 전달용 조성물 |
| CL2014003514A1 (es) * | 2014-12-23 | 2015-05-08 | Univ De Concepción | Nanopartículas a base de quitosano para el transporte de péptidos con actividad en el sistema nervioso central. |
| KR101916193B1 (ko) | 2016-08-25 | 2018-11-07 | 주식회사 파마리서치프로덕트 | 핵산 및 키토산을 포함하는 관절강 주사용 조성물 |
| EP3612215B1 (en) | 2017-04-20 | 2024-08-28 | aTyr Pharma, Inc. | Compositions for treating lung inflammation |
| PE20210685A1 (es) | 2018-07-03 | 2021-04-08 | Gilead Sciences Inc | Anticuerpos que se dirigen al gp120 de vih y metodos de uso |
| PE20220231A1 (es) | 2019-06-25 | 2022-02-07 | Gilead Sciences Inc | Proteinas de fusion flt3l-fc y metodos de uso |
| EP3999107A1 (en) | 2019-07-16 | 2022-05-25 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
| EP4458975A3 (en) | 2019-09-30 | 2025-02-12 | Gilead Sciences, Inc. | Hbv vaccines and methods treating hbv |
| CA3128035A1 (en) | 2020-08-13 | 2022-02-13 | Bioasis Technologies, Inc. | Combination therapies for delivery across the blood brain barrier |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| CN119677546A (zh) | 2022-07-12 | 2025-03-21 | 吉利德科学公司 | Hiv免疫原性多肽和疫苗及其用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6008202A (en) | 1995-01-23 | 1999-12-28 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US7052678B2 (en) | 1997-09-15 | 2006-05-30 | Massachusetts Institute Of Technology | Particles for inhalation having sustained release properties |
| EP1045699A1 (en) * | 1998-01-16 | 2000-10-25 | The Johns Hopkins University | Genetic immunization with co-delivery of nucleic acid and cytokines in a single vehicle |
| US20030134810A1 (en) * | 2001-10-09 | 2003-07-17 | Chris Springate | Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents |
| WO2004074314A2 (en) * | 2003-02-14 | 2004-09-02 | University Of South Florida | Chistosan-microparticles for ifn gene delivery |
| KR100882611B1 (ko) * | 2006-11-14 | 2009-02-12 | 주식회사 키토라이프 | 표적 리간드로서 폴릭산이 도입된 유전자 전달체용저분자량 수용성 키토산 나노입자 및 이의 제조방법 |
| KR100825519B1 (ko) | 2007-01-05 | 2008-04-25 | 주식회사 바이오폴리메드 | 키토산 기재 고분자 접합체 및 그 제조방법 |
| US20110038941A1 (en) | 2007-12-27 | 2011-02-17 | The Ohio State University Research Foundation | Lipid Nanoparticle Compositions and Methods of Making and Using the Same |
| KR101494594B1 (ko) | 2011-08-30 | 2015-02-23 | 주식회사 종근당 | 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물 |
-
2011
- 2011-11-10 KR KR1020110117082A patent/KR101383324B1/ko active Active
-
2012
- 2012-11-09 EP EP12847217.2A patent/EP2776056B1/en active Active
- 2012-11-09 ES ES12847217.2T patent/ES2621403T3/es active Active
- 2012-11-09 JP JP2014540950A patent/JP5923177B2/ja active Active
- 2012-11-09 US US14/357,375 patent/US9173853B2/en active Active
- 2012-11-09 WO PCT/KR2012/009443 patent/WO2013070010A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015501791A5 (enExample) | ||
| JP2013542247A5 (enExample) | ||
| EA201170039A1 (ru) | Полимерные частицы, нагруженные лекарственным средством, и способы их получения и применения | |
| JP2013507423A5 (enExample) | ||
| WO2014004436A3 (en) | Crystalline anti-human il-23 antibodies | |
| BR112014014599A8 (pt) | polímeros de alfa-aminoamidina e uso dos mesmos | |
| EA201890236A1 (ru) | Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение | |
| JP2013032389A5 (enExample) | ||
| SG10201804024VA (en) | Formulations of azaindole compounds | |
| HK1214499A1 (zh) | 穩定的低粘度抗體配製品 | |
| MD20140073A2 (en) | New phosphate compounds, a process for their preparation and pharmaceutical compositions containing them | |
| JP2015007131A5 (enExample) | ||
| MA35130B1 (fr) | Composition comprenant de l'aflibercept, de l'acide folinique, du 5-fluoro-uracile (5-fu) et de l'irinocetan (folfiri) | |
| MY178888A (en) | Dialysis a agent comprising acetic acid and acetate, and two-part dialysis agent using same | |
| JP2014097964A5 (enExample) | ||
| JP2017517533A5 (enExample) | ||
| CA2920410C (en) | Thienopiperidine derivative and use thereof | |
| JP2015509075A5 (enExample) | ||
| JP2013518036A5 (enExample) | ||
| JP2013535445A5 (enExample) | ||
| WO2014081968A8 (en) | Compositions of low sodium salt and methods of making and using | |
| JP2014500250A5 (enExample) | ||
| WO2010080754A3 (en) | Nanoparticle pharmaceutical formulations | |
| DOP2011000032A (es) | Composicion farmaceutica solida | |
| RU2015110285A (ru) | Материалы носителя катализатора, катализаторы, способы их получения и применения |